SLC5A2 and metabolic dysfunction-associated steatotic liver disease: The results suggested that SGLT2 inhibitors reduced the AST levels in patients with NAFLD and had superior effect over pioglitazone (WMD -1.28 [95% CI: -2.23, -0.33], p = 0.008) and metformin (WMD -3.80[95% CI: -5.07, -2.53], p < 0.00001) (Figure 6).